Bryan Johnson
Showing 1–8 of 8 transcripts.
- All-In Podcast38 min
Bryan Johnson: I Just Took the Most Powerful Dose of DMT in the World... Here's What It Was Like
Bryan Johnson, David Friedberg
Brian Johnson reports that ingesting a high dose of 5-MeO-DMT induced a 48-hour session of total ego dissolution, effectively annihilating the brain's Default Mode Network to produce a profound metabolic reset and restored youthful neural connectivity. He interprets these neurological changes as a critical mechanism for anti-aging and psychological rejuvenation, complementing his broader longevity protocols that include mitochondrial transplantation, FoxO3 gene therapy, and personalized stem cell organoids. By framing psychedelics as essential tools for "psycho-flexibility" against rapid AI-driven change, Johnson aims to normalize these interventions while acknowledging the risks of unregulated use and the philosophical implications for personal identity.
- All-In Podcast11 min
Bryan Johnson’s Best Health Hack: Lower Your RHR Before Sleep = Sleep Better and Live Longer
Brian Johnson presents an ambitious framework positioning the indefinite extension of human life as a new global ideology, utilizing biological age testing to illustrate that organs age independently and require targeted management. He identifies resting heart rate as the primary health metric and details a specific protocol involving strict sleep hygiene, diet timing, and screen discipline to lower this rate by approximately 10%. This approach aims to reverse aging trends while simultaneously treating sleep as the fundamental intervention for anxiety and depression, ultimately preparing humanity for a future defined by superintelligence.
Ashlee Vance: Stories from Elon, Palmer Luckey, Bryan Johnson & Priscilla Chan
Ashlee Vance, Elon, Palmer Luckey, Bryan Johnson, Priscilla Chan, Molly O'Shea
Host Molly O'Shea and guest Brian Johnson dissect the extreme work ethic and polarizing influence of Elon Musk while contrasting his relentless pace with Johnson's strategic shift from full-time influence to frontier science research. The conversation further explores the host's high-risk personal experiences, ranging from radiation exposure in Soviet nuclear sites to testing unconventional self-driving vehicles, alongside a skeptical analysis of the current realities of quantum computing and fusion energy. Finally, the dialogue outlines future podcast expansions into deep-dive biotech investigations and reflects on the dynamics of corporate travel culture through the lens of the host's record-breaking expense reports at Bloomberg.
- All-In Podcast1h 50m
All-In Live from Austin: Colin and Samir, Chris Williamson, and Bryan Johnson
Colin, Samir, Chris Williamson, Bryan Johnson, Friedberg, Jason, Chamath
Major legacy media giants are aggressively reorganizing their strategies to compete with an independent creator economy that now dominates connected TV viewership through superior algorithmic retention and authentic long-form content. Top creators are increasingly rejecting traditional media deals to retain full intellectual property ownership, pivoting instead toward lean business models that prioritize direct product sales, high-value physical events, and 360-degree brand partnerships. This structural shift is further accelerated by new monetization vectors such as health-focused consumer goods and experimental physiological research, which collectively challenge the historical dominance of legacy broadcast networks.
- The Diary Of A CEO1h 43m
I've PROVEN This Food Keeps You Young & This Oil Reduces Inflammation by 85%! Bryan Johnson
Brian Johnson has launched the commercial "Blueprint" protocol, a $2 million annual biohacking regimen combining advanced gene therapy, strict nutritional timing, and over 60 daily supplements to reverse biological aging. The program's scalability is being validated by Kate Tolo, who transitioned from health markers equivalent to a 70-year-old to elite athletic performance within 90 days while adhering to Johnson's precise schedule. Framed as a necessary evolution against impending artificial superintelligence, the initiative seeks to democratize radical life extension by making its full dietary and exercise data publicly available despite the high financial and physiological costs involved.
- The Diary Of A CEO2h 3m
The Man Thats Ageing Backwards: “I Was 45, I’m Now 18!” - Bryan Johnson
Entrepreneur and longevity researcher Brian Johnson has abandoned his $800 million tech exit to pursue a singular mission of indefinite human survival by treating the body as an algorithm-led system. Johnson enforces a rigorous "Blueprint" protocol involving 111 daily supplements, strict caloric limits, and sleep optimization to reverse his biological age, while arguing that aligning humanity's fragmented goals with the "don't die" imperative is essential to prevent collapse from AI misalignment or environmental degradation. This radical shift from traditional decision-making aims to transform the 35 trillion cells of the human body into a unified cooperative unit, creating a foundational template for global survival before artificial intelligence surpasses human governance.
- Lex Fridman2h 32m
Bryan Johnson: Kernel Brain-Computer Interfaces | Lex Fridman Podcast #186
Brian Johnson founded Kernel to deploy the non-invasive Kernel Flow device, a portable system using 52 spectroscopy modules to monitor brain activity in everyday environments without the constraints of fMRI or EEG. By prioritizing high-quality data collection over immediate applications, the company aims to establish a mass-market ecosystem that enables the "formal engineering of cognition" and facilitates goal alignment between biological, AI, and planetary systems. This approach contrasts with invasive competitors like Neuralink by seeking a low-resolution but ubiquitous data stream, ultimately aiming to democratize access to neural insights while enforcing strict individual consent models for brain data privacy.
- Milken Institute1h 1m
World-class Healthcare: Investing in Biomedical Innovation
Tanisha Carino, Christopher Hite, Bryan Johnson, Sean Parker, D.A. Wallach
Moderated by Dr. Tanisha Carino in Abu Dhabi, this session analyzed the convergence of global biomedical innovation and market dynamics, highlighted by the historic $92 billion Bristol-Myers Squibb acquisition of Celgene as a catalyst for pipeline stability. The discussion detailed how falling hard science costs and platforms like Ginkgo Bioworks are compressing development timelines, while investment strategies increasingly favor foundational tools over singular disease treatments to address the translational gap between academic research and commercial viability. Despite concerns regarding venture capital concentration in oncology and systemic US healthcare incentives, the event projected that long-term pricing decreases and extended lifespans could emerge from global regulatory evolution and the integration of AI-driven data collection.